BackgroundHeart failure frequently coexists with cardiometabolic conditions commonly associated with metabolic syndrome. Characterizing long-term mortality patterns involving these co-reported conditions may help identify populations with a disproportionate burden. MethodsWe performed a national serial cross‑sectional analysis using the CDC WONDER Multiple Cause of Death database to examine mortality among U.S. adults aged ≥25 years from 1999 to 2023. Eligible deaths included those with at least one heart failure ICD‑10 code and at least one metabolic syndrome–related ICD–10 code recorded anywhere on the death record. Age‑adjusted mortality rates (AAMRs) per 100,000 population were calculated using the 2000 U.S. standard population. Temporal trends were assessed using Joinpoint regression and stratified by sex, race/ethnicity, U.S. Census region, urbanization (1999–2020), and state. ResultsA total of 1,562,715 deaths co‑reporting heart failure and metabolic syndrome–related conditions were identified. The overall AAMR increased from 24.7 in 1999 to 38.3 in 2023. After declining from 2005 to 2012, mortality increased beginning in the mid-2010s, with a pronounced acceleration during 2018–2021 and a modest decline thereafter. AAMRs were higher among men, non-Hispanic Black and American Indian or Alaska Native populations, residents of the Midwest (with comparatively elevated rates also observed in the West and South), and individuals in nonmetropolitan areas. ConclusionsMortality involving deaths co‑reporting heart failure and metabolic syndrome–related conditions increased substantially after 2012, with marked disparities by sex, race/ethnicity, geography, and urbanization, underscoring the need for equity‑focused cardiometabolic prevention strategies.
Introduction: Aortic stenosis (AS) and atrial fibrillation (AF) frequently coexist in older adults and are associated with increased cardiovascular risk. National mortality trends involving both conditions remain incompletely characterized. Methods: We performed a nationwide ecological time-trend analysis using the CDC WONDER Multiple Cause of Death database from 1999 to 2024. Adults aged ≥ 55 years with both AS (ICD-10 I35.0) and AF (ICD-10 I48) listed on the death certificate were included. Age-adjusted mortality rates (AAMRs) per 100,000 populations were analyzed overall and by sex, race/ethnicity, census region, urbanization, and place of death. Temporal trends were assessed using Joinpoint regression. Results: A total of 94,542 deaths involving AS and AF were identified. Overall AAMR increased from 2.4 (95% confidence interval [CI], 2.3–2.6) in 1999 to 7.4 (95% CI, 7.2–7.6) in 2024, with a significant overall increase (average annual percent change [AAPC], 5.08%; p < 0.001). Mortality remained higher among males than females (2024 AAMR: 9.2 vs. 6.1 per 100,000). NH White individuals had the highest mortality rates, while all racial and ethnic groups demonstrated significant increases over time. Mortality was highest in the Western United States and in non-metropolitan areas. Most deaths occurred in inpatient facilities (33.8%), followed by home (29.0%) and nursing homes or long-term care facilities (22.6%). Conclusion: Mortality involving coexisting AS and AF increased more than threefold among U.S. adults aged ≥ 55 years between 1999 and 2024. Persistent demographic and geographic disparities highlight the need for earlier diagnosis and improved access to guideline-directed care. Clinical trial number: Not applicable.